Image

Global Immune-Mediated Inflammatory Diseases Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Oct 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Immune-Mediated Inflammatory Diseases Market, By Treatment Type (Traditional Drugs, Biologic Therapies, Novel Therapies), Indication (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.

Immune-Mediated Inflammatory Diseases Market

Immune-Mediated Inflammatory Diseases Market Analysis and Size

The global immune-mediated inflammatory diseases market is expected to witness significant growth during the forecast period. Wide availability of advanced treatment facilities at quite low prices in developing countries, such as India and China, as compared to that in the West is a primary factor boosting the immune-mediated inflammatory disease treatment market in Asia-Pacific. Cardiovascular and respiratory diseases have affected many individuals worldwide, and are the top cause of death among the global population. COVID-19 also had left a major impact on the population and the market growth.

Data Bridge Market Research analyses a growth rate in the global immune-mediated inflammatory diseases market in the forecast period 2022-2029. The expected CAGR of global immune-mediated inflammatory diseases market tend to be around 6.50% in the mentioned forecast period. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Immune-mediated inflammatory disease (IMID) is defined as a group of unrelated conditions which lack a definitive etiology, but share a common inflammatory pathway leading to inflammation. Immune-mediated diseases are conditions triggered by over-activity or abnormal activity of the body’s immune system. All immune-mediated inflammatory diseases (IMID) can cause organ damage, and are associated with increased morbidity and/or mortality.

Immune-Mediated Inflammatory Diseases Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment Type (Traditional Drugs, Biologic Therapies, Novel Therapies), Indication (Asthma, Chronic Obstructive Pulmonary Diseases (COPD), Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S.), Zydus Group (India), Akorn, Incorporated (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan)

Market Opportunities

  • Increase in Elderly Population
  • Rising Autoimmune Disorders

Global Immune-Mediated Inflammatory Diseases Market Dynamics

Drivers

  • High Prevalence of Arthritis

Its been witnessed that more than 350 million people have arthritis all over the globe. In the U.S., 1 in 4 adults have been reported with arthritis in 2020. It’s estimated to be 78 million by the year 2040. This boosts the market growth.

  • Rising Healthcare Expenditure

Since the last few decades, it has been witnessed that global per capita healthcare spending has improved considerably due to the rising rate of awareness associated with the availability of treatments and diagnostic methods for treating various diseases. More and more healthcare spending is likely to result in increasing demand for better diagnostic methods, which in turn, create high growth opportunities for market players operating in treating allergic and asthmatic conditions in the market.

Opportunities

  • Increase in Elderly Population

Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies.

  • Rising Autoimmune Disorders

The number of people affected with autoimmune diseases is increasing steadily across the world. The primary cause of a number of these diseases can be traced to a lack of healthy lifestyle and dietary habits and genetics that can activate these diseases. An increase in these diseases boosts the global immune-mediated inflammatory disease market.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel unable to perform the treatments could curb the growth of the global immune-mediated inflammatory disease market over a forecast period.

  • Side-Effects of immune-mediated inflammatory disease drugs

The adverse side-effects associated with the treatment process hamper the market growth. Effects such as skin rash and also some immunosuppressive drugs can lead to autoimmune reactions.

This global immune-mediated inflammatory diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global immune-mediated inflammatory diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Immune-Mediated Inflammatory Diseases Market

With the onset of COVID-19, several countries abandoned all non-emergency surgical procedures so that healthcare professionals only focus on patients with COVID-19. Thus, the market faced a huge loss during the pandemic. It has been witnessed that people with immune-mediated inflammatory diseases have a comparatively higher risk of COVID-19-related death, critical care admission or death, and hospital admissions than people without immune-mediated inflammatory diseases of the sex, deprivation level, same age, and smoking status. In addition to this, adults with inflammatory joint disease had a superior increase in risk of all outcomes than those with inflammatory skin or bowel disease. Thus, COVID-19 left a major impact on the market.

Global Immune-Mediated Inflammatory Diseases Market Scope

The global immune-mediated inflammatory diseases market is segmented on the basis of indication, treatment type, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Asthma, Chronic Obstructive Pulmonary Diseases (COPD)
  • Inflammatory Bowel Disease (IBD)
  • Systemic Lupus Erythematosus (SLE)
  • Rheumatoid Arthritis (RA)
  • Psoriasis
  • Others

Treatment Type

  • Traditional Drugs
  • Biologic Therapies
  • Novel Therapies

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Global Immune-Mediated Inflammatory Diseases Market Regional Analysis/Insights

The global immune-mediated inflammatory diseases market is analyzed and market size insights and trends are provided by indication, treatment type, route of administration, end-user and distribution channel as referenced above.

The major countries covered in the global immune-mediated inflammatory diseases market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to rise in the prevalence of the disease, rise in the healthcare affordability.

Asia-Pacific is expected to account for the largest market due to the rise in the knowledge and awareness of this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Immune-Mediated Inflammatory Diseases Market Share Analysis

The global immune-mediated inflammatory diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global immune-mediated inflammatory diseases market

Key players operating in the global immune-mediated inflammatory diseases market include:

  • Pfizer Inc. (U.S.)
  • Abbvie Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Amgen Inc. (U.S.)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Merck & Co Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • AstraZeneca (U.K.)
  • Ampio Pharmaceuticals Inc. (U.S.)
  • Lilly (U.S)
  • Zydus Group (India)
  • Akorn, Incorporated (U.S.)
  • DAIICHI SANKYO COMPANY, LIMITED (Japan)


SKU-

Why Choose Us


Frequently Asked Questions

The Immune-Mediated Inflammatory Diseases Market is projected to grow at a CAGR of 6.50% during the forecast period by 2029.
The key opportunities in the Immune-Mediated Inflammatory Diseases Market in terms of increase in Elderly Population, rising Autoimmune Disorders.
The major players in the Immune-Mediated Inflammatory Diseases Market are Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), etc.
The country covered in the Immune-Mediated Inflammatory Diseases Market is U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, etc.
Factors such as high prevalence of arthritis and rising healthcare expenditure are acting as the major drivers for the global immune-mediated inflammatory diseases market.